angiogenic gene therapy


Agent

AGENT
Angiogenic GENe Therapy. A clinical trial evaluating the safety & efficacy of an angiogenic gene therapy, Ad5-FGF4 (fibroblast growth factor 4).
Primary endpoint 1-month, 3-month exercise tolerance.
Conclusion Early data indicate that Ad5-FGF4 significantly improves exercise time in treated patients.
Agent
Choice in dying An adult appointed by the declarant, under an advance directive executed or made in accordance with the legal provisions, to make health care decisions for the declarant. VA Bd of Medicine, 1997-98 § 54.1-2982
Epidemiology A factor (such as a microorganism, chemical substance, or form of radiation) whose excessive presence, or relative absence (in deficiency states), is essential for the occurrence of a disease.
Health insurance An insurance company representative licensed by the state who solicits, negotiates, or effects insurance contracts and who provides services to the policyholder for the insurer.
Infomatics A small mobile piece of computer software that can send itself across a computer network and perform a task on a remote machine.
Medspeak A thing capable of producing an effect.
Military A code term for a biological substance that can be used as a weapon of mass destruction.
Nutrition A substance added to a food to change a physical property.
Pharmaceutical industry An authorised person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser, not including a common or contract carrier, public warehouseman, or employee of the carrier warehouseman. VA Bd of Pharmacy, 7/97.
Pharmacology Any substance capable of producing a physical, chemical or biologic effect.
Virology An unidentified virus or pathogen.

angiogenic gene therapy

Cardiology An investigational therapy that delivers a growth factor gene to diseased coronary arteries evoking growth factor production and stimulating angiogenesis and formation of blood vessels that bypass occluded coronary arteries